Targeted Therapy in Ovarian Cancer
Ovarian cancer (OC) is associated with a dismal prognosis and lack of curative treatment. Increased understanding of OC biology has led to the development of several targeted therapies, including antiangiogenic agents and poly(ADP-ribose) polymerase (PARP) inhibitors. Cell cycle inhibitors and endoc...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2021-06-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2021.08.033 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Ovarian cancer (OC) is associated with a dismal prognosis and lack of curative treatment. Increased understanding of OC biology has led to the development of several targeted therapies, including antiangiogenic agents and poly(ADP-ribose) polymerase (PARP) inhibitors. Cell cycle inhibitors and endocrine therapy such as selective estrogen receptor down regulators are currently under development. In this article, we provide an overview of the current and emerging targeted therapies in OC. |
|---|---|
| ISSN: | 2673-2106 |